Alder Biopharmaceuticals

Alder Biopharmaceuticals

Based: Bothell, WA
Raised: $38 million
Investors: Delphi Ventures, H.I.G. Capita, Novo A/S, Sevin Rosen Funds, TPG Growth, Ventures West Management, WRF Capital

The scoop: Armed with a promising approach to antibody development and partnered with Bristol-Myers Squibb ($BMY) on a rich development deal, Bothell, WA-based Alder snapped up a $38 million venture round. Alder last raised venture cash four years ago. The biotech's Series C had contributed $40 million in 2007. Then BMS signed up for a $1.07 billion pact in 2009, paying $85 million upfront to partner on Alder's lead program, an IL-6 inhibitor for rheumatoid arthritis--ALD518. Alder is studying ALD518 in mid-stage cancer trials while BMS pursues a program for autoimmune diseases. The new money will also be used to put ALD403, Alder's calcitonin gene-related peptide (CGRP) inhibiting antibody therapeutic, in the clinic for migraine. And there's also a PCSK9 program--for dyslipidemia--that's in the wings. Alder was named a Fierce 15 company in 2010.

Alder Biopharmaceuticals

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.